S022 Late-Breaking Research: Session 1
DESCRIPTION
The Late Breaking Abstract Sessions showcase the most timely, high-impact, and unpublished research across the full spectrum of dermatology. Through a rigorous peer-review process, top-scoring submissions are selected for concise oral presentations that emphasize novelty and clinical relevance. This session features practice-changing clinical trials, population-based investigations, transformative technologies, translational biomarker studies, and innovative basic science. Abstracts addressing skin, hair, and nail disorders will be highlighted, with particular emphasis on discoveries that deepen understanding of disease mechanisms, inform therapeutic development, or improve the prevention and management of adverse events.
LEARNING OBJECTIVES
Evaluate late-breaking clinical, translational, and basic science studies for scientific rigor, novelty, and relevance to advancing dermatologic disease mechanisms and therapy.
Apply emerging evidence from trials, population studies, and biomarkers to improve clinical decision-making, patient outcomes, and prevention of adverse events.
Identify how novel discoveries and technologies impact dermatologic practice and healthcare systems, including implications for prevention, risk stratification, and multidisciplinary care.
DIRECTOR
Hensin Tsao, MD, PhD, FAAD
Harvard Medical School
MODERATORS
April W. Armstrong, MD, MPH, FAAD
University of California Los Angeles
Aaron Mark Drucker, MD, FAAD
University of Toronto
Joel M. Gelfand, MD, MSCE, FAAD
University of Pennysylvania Perelman School of Medicine
Kenneth B. Gordon, MD, FAAD
Paul Nghiem, MD, PhD, FAAD
DISCLOSURES
April W. Armstrong, MD, MPH, FAAD
AbbVie – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Alumis – Investigator(Grants/Research Funding); Amgen – Advisory Board(Honoraria); Arcutis Biotherapeutics – Consultant(Honoraria); Boehringer Ingelheim – Data Safety Monitoring Board(Honoraria); Bristol-Myers Squibb – Consultant (1099 relationship)(Honoraria); Dermsquared – Advisory Board(Honoraria); Eli Lilly and Company – Advisory Board(Honoraria); Galderma USA – Advisory Board(Honoraria); Incyte – Consultant (1099 relationship)(Honoraria); Janssen Biotech – Consultant (1099 relationship)(Honoraria); Leo Pharma Inc – Consultant(Honoraria); Novartis – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Oruka Therapeutics – Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Honoraria); Regeneron – Advisory Board(Honoraria); Sanofi Genzyme – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); UCB – Advisory Board(Honoraria);
Aaron Mark Drucker, MD, FAAD
No financial relationships exist with ineligible companies.
Joel M. Gelfand, MD, MSCE, FAAD
AbbVie – Consultant(Fees); Alumis – Consultant (1099 relationship)(Fees); Alyson Oliver Partner & Attorney – Consultant (1099 relationship)(Fees); Arcutis Biotherapeutics – Consultant (1099 relationship)(Fees); Arnold & Porter – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); Bristol Myers Squibb – Investigator(Grants/Research Funding); Eli Lilly and Company – Investigator(Grants/Research Funding); FIDE – Consultant(Fees); Healio – Other(Fees); Inmagene Biopharmaceuticals – Data Safety Monitoring Board(Fees); International Psoriasis Council – Board of Directors(No Compensation Received); Johnson & Johnson Innovative Medicine – Consultant (1099 relationship)(Fees); Leo Pharma Inc – Consultant(Fees); Maui Derm – Speaker/Faculty Education(Fees); Medical Dermatology Society – Board of Directors(No Compensation Received); Moonlake – Data Safety Monitoring Board(Fees); National Psoriasis Foundation – Investigator(Grants/Research Funding); Neuroderm LTD – Other(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees);
Kenneth B. Gordon, MD, FAAD
AbbVie – Consultant(Honoraria), Investigator(Grants/Research Funding); Almirall – Consultant(Honoraria); Amgen – Consultant(Honoraria); Arcutis, Inc. – Consultant(Honoraria); Boehringer Ingelheim – Consultant(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Consultant(Honoraria); Dermavant Sciences – Consultant(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); Incyte Corporation – Consultant(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Leo Pharma Inc – Consultant(Honoraria); Lilly ICOS LLC – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); Novartis Pharmaceuticals Corp. – Advisory Board(Honoraria); Othro Dermatologics – Consultant(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); Protagonist Therapeutics – Consultant (1099 relationship)(Honoraria); Sanofi Genzyme – Consultant(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); UCB – Consultant(Honoraria);
Paul Nghiem, MD, PhD, FAAD
Almirall – Consultant(Honoraria); Incyte Corporation – Other(Grants/Research Funding); TuHURA Biosciences – Data Safety Monitoring Board(Honoraria);
Hensin Tsao, MD, PhD, FAAD
Epiphany Dermatology – Advisory Board(Honoraria), Advisory Board(Stock Options); Massachusetts General Hospital – Employee(Salary); UpToDate, Inc. – Other(Honoraria);